新闻
HROW
--
0.00%
--
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
NASHVILLE, Tenn., January 10, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright ...
Business Wire · 01/10 11:45
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
NASHVILLE, Tenn., January 04, 2022--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two investigational new drug applications (INDs) with the ...
Business Wire · 01/04 13:00
Select Medical's (SEM) Rising Stake in Concentra to Aid
Zacks.com · 01/02 00:24
Harrow Health Added to the Nasdaq Biotechnology Index
NASHVILLE, Tenn., December 13, 2021--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20...
Business Wire · 2021/12/13 13:00
EyePoint, ImprimisRx expand commercial alliance for Dexycu eye corticosteroid
EyePoint Pharmaceuticals (NASDAQ:EYPT) and ImprimisRx, a subsidiary of Harrow Health (NASDAQ:HROW), have expanded an alliance under which Imprimis is now responsible for marketing of Dexycu (dexamethasone intraocular suspension) for post-operative
Seekingalpha · 2021/12/07 22:20
EyePoint Pharma Reports Expanded US Commercial Alliance For DEXYCU With Harrow Health
ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint’s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue
Benzinga · 2021/12/07 21:32
Why Seasoned Investors are Retaining Select Medical (SEM) Stock
Zacks.com · 2021/12/06 16:54
阿卡迪亚 (ACHC) 和奥兰多健康组建合资企业,提升存在感
Zacks.com · 2021/12/02 15:05
Why Seasoned Investors are Retaining Acadia (ACHC) Stock
Zacks.com · 2021/11/30 15:50
Harrow (HROW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks.com · 2021/11/29 15:00
哈罗 (HROW) 的盈利预测走高:是时候买入了?
Zacks.com · 2021/11/19 17:20
Teladoc (TDOC) Falls 8.1% Despite Upbeat Revenue Guidance
Zacks.com · 2021/11/19 17:06
Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of 66.67% and 8.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2021/11/09 23:25
BRIEF-Harrow Health Posts Quarterly Loss Per Share Of $0.31
reuters.com · 2021/11/09 21:44
Harrow Health Q3 EPS $(0.31) Down From $0.32 YoY, Sales $18.70M Beat $17.45M Estimate
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.31) per share. This is a 196.88 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of
Benzinga · 2021/11/09 21:07
BRIEF-Harrow Health And NDS Entered Voluntary Settlement Agreement
reuters.com · 2021/11/09 13:16
--Aegis Capital 以 15 美元的目标价启动 Harrow Health
MT Newswires · 2021/09/24 10:50
调查 Harrow Health 的资本使用回报率
According to Benzinga Pro, during Q2, Harrow Health (NASDAQ:HROW) earned $4.17 million, a 72.13% increase from the preceding quarter. Harrow Health also posted a total of $18.13 million in sales, a 17.43% increase since Q1.
Benzinga · 2021/09/22 16:32
高达 1.25 亿美元的混合货架的 BRIEF-Harrow Health 文件
reuters.com · 2021/09/03 21:16
微牛提供丰富的实时HROW股票新闻,让你可以通过多个平台了解HROW股票行情最新动态,这些免费的Harrow Health Inc新闻可以帮助你做出明智投资。
HROW 简况
Harrow Health Inc是一家专注于眼科的医疗保健公司。该公司拥有并经营ImprimisRx(一家专注于眼科的制药业务)和Visionology(一家专注于慢性眼病的直接面向消费者的眼科护理子公司)。该公司持有Eton Pharmaceuticals、Surface Ophthalmics和Melt Pharmaceuticals的非控股股权。该公司还拥有四种临床阶段候选药物的特许权使用权,这些候选药物由Surface Ophthalmics和Melt Pharmaceuticals开发。